Neonc Technologies Holdings宣布口服抗癌药物Neo212的一期临床试验剂量递增阶段数据。研究明确了药物的安全剂量范围与毒性特征,并成功确定了二期临床试验推荐使用剂量。
公司管理层将于美东时间今日上午9点举办关键意见领袖电话会议,深入解读临床数据及后续开发计划。
Neonc Technologies Holdings宣布口服抗癌药物Neo212的一期临床试验剂量递增阶段数据。研究明确了药物的安全剂量范围与毒性特征,并成功确定了二期临床试验推荐使用剂量。
公司管理层将于美东时间今日上午9点举办关键意见领袖电话会议,深入解读临床数据及后续开发计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.